指南与共识脊柱关节炎

生物类改善病情抗风湿药治疗中轴型脊柱关节炎的疗效与安全性:为2022年ASAS-EULAR中轴型脊柱关节炎管理建议更新提供信息的系统文献综述

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
指南 / 共识 · Ann Rheum Dis · 2022-10-21

该系统文献综述(2016-2021年)评估了生物类改善病情抗风湿药在中轴型脊柱关节炎中的疗效与安全性,共纳入148篇文献。结果支持TNF抑制剂(原研/生物类似药)和IL-17抑制剂在放射学和非放射学中轴型脊柱关节炎中的疗效与安全性,而IL-23抑制剂未显示相关获益;观察性研究需进一步确认IL-17抑制剂的长期安全性。

要点

  • TNF抑制剂(原研/生物类似药)和IL-17抑制剂在r-axSpA和nr-axSpA中显示疗效与安全性。
  • IL-23和IL-12/23抑制剂(risankizumab/ustekinumab)未能显示相关获益。
  • 观察性研究显示司库奇尤单抗(n=1)和依那西普(n=2)与单克隆TNF抑制剂相比葡萄膜炎风险增加。

核心结论

  • 新证据支持TNF抑制剂(原研/生物类似药)和IL-17抑制剂在放射学和非放射学中轴型脊柱关节炎中的疗效与安全性,而IL-23抑制剂未能显示相关效果。

研究设计与样本

  • 系统文献综述(2016-2021年),纳入随机对照试验、策略试验和观察性研究(观察性研究仅用于安全性和肌肉骨骼外表现),共纳入148篇文献。

主要发现

  • 戈利木单抗和赛妥珠单抗的疗效得到确认,TNF抑制剂生物类似药与原研药等效性得到证实。
  • 15项随机对照试验数据显示IL-17抑制剂具有临床相关效应,达到ASAS40缓解的风险比 vs 安慰剂为1.3-15.3(r-axSpA,n=9)和1.4-2.1(nr-axSpA,n=2)。
  • 司库奇尤单抗/依奇珠单抗在TNF抑制剂初治和TNF抑制剂应答不足患者中显示疗效。
  • IL-23和IL-12/23抑制剂(risankizumab/ustekinumab)未能显示相关获益。
  • 通过延长给药间隔进行TNF抑制剂减量不劣于标准剂量治疗;首个axSpA达标治疗试验未达到主要终点,但次要结局有改善。

关键数值与推荐

  • 观察性研究中TNF抑制剂使用未发现新风险(IL-17抑制剂数据缺乏)。
  • 观察性研究显示司库奇尤单抗(n=1)和依那西普(n=2)与单克隆TNF抑制剂相比葡萄膜炎风险增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察性研究需进一步确认IL-17抑制剂的长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2016-2021) on efficacy and safety of bDMARDs in axSpA (radiographic axSpA (r-axSpA)/non-radiographic axSpA (nr-axSpA)). Eligible study designs included randomised controlled trials (RCTs), strategy trials and observational studies (the latter only for safety and extra-musculoskeletal manifestations). All relevant efficacy/safety outcomes were included. RESULTS: In total, 148 publications were included. Efficacy of golimumab and certolizumab was confirmed. Tumour necrosis factor inhibitor (TNFi) biosimilar-originator equivalence was demonstrated. RCT (n=15) data on efficacy of interleukin-17 inhibitors (IL-17i) demonstrated clinically relevant effects (risk ratio vs placebo to achieve ASAS40 response 1.3-15.3 (r-axSpA, n=9), 1.4-2.1 (nr-axSpA, n=2)). Efficacy of secukinumab/ixekizumab was demonstrated in TNFi-naïve and TNFi-inadequate responders. IL-23 and IL-12/23 inhibitors (risankizumab/ustekinumab) failed to show relevant benefits. Tapering of TNFi by spacing was non-inferior to standard-dose treatment. The first axSpA treat-to-target trial did not meet its primary endpoint, but showed improvements in secondary outcomes. No new risks were identified with TNFi use in observational studies (data lacking for IL-17i). Secukinumab (n=1) and etanercept (n=2) were associated with increased risk of uveitis in observational studies compared to monoclonal TNFi. CONCLUSIONS: New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA, while IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. PROSPERO REGISTRATION NUMBER: CRD42021257588.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Webers C, Ortolan A, Sepriano A, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2022. PMID: 36270657. doi:10.1136/ard-2022-223298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。